Panuri Performance Study

Inclusion Criteria: * Arm 1 (Target Arm): * Adults 18 years and older * Presenting with symptoms supporting a clinical suspicion for pancreatic cancer by the healthcare provider, including but not limited to jaundice, abdominal or back pain, fatty stools, unexplained weight loss, loss of appetite, chronic fatigue, nausea, vomiting, indigestion, bloating, gas, diarrhea, constipation, itching, dark urine, fever, and swelling of the legs. * Arm 2 (Enriched Arm): * Adults 18 years and older * Scheduled for a procedure involving pancreatic histopathological assessment due to suspicion of pancreatic cancer. Exclusion Criteria: * For subjects in the enriched arm, imaging results are highly suspicious for non-PDAC pancreatic cancer. * Patients enrolled in a pancreatic cancer screening program. * Prior diagnosis of pancreas malignancy, including pathological diagnoses and suspicion of pancreatic cancer based on clinical, histopathological or radiological results. Exceptions include: pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasms (IPMN), mucinous cystadenoma of the pancreas (MCN), serous cystadenomas (SCN) or other benign pancreatic lesions and cystic lesions without features suggestive of malignancy. * History of pancreatic resection * Presenting with concurrent symptoms or suspicion of urinary tract infection Diagnosis of any urinary tract infection within the last 30 days, except for cases that have been resolved with antibiotics discontinued at least 14 days prior to enrollment * Diagnosed with stage 3b to 5 chronic kidney diseases (CDK3b-CDK5), acute kidney disease in last 3 months, nephrotic syndrome in the last 6 months, or other kidney diseases associated with proteinuria * Diagnosed with any conditions that increase bilirubin levels within the last 6 months * Self-reported or documented elevated blood bilirubin levels within the past 3 months, defined as exceeding 1.5 times the upper limit of normal specific to the test laboratory * Diagnosis of any cancer within the past 5 years * Chemotherapy or anti-neoplastic therapy within the last 5 years * Any medical or psychological conditions that preclude compliance with study procedures. * Patients without any clinical signs or symptoms of pancreatic cancer * Inability to provide written informed consent. * Pregnant or breastfeeding women * Current participation in another drug or device study or planned participation prior to completion of sample collection procedures (i.e., approximately 1.5 months)